Trial ID or NCT#



not recruiting iconNOT RECRUITING


Randomized trial of adults (≥18 years old) with idiopathic intracranial hypertension and moderate to severe visual loss without substantial recent treatment who are randomly assigned to (1) medical therapy, (2) medical therapy plus ONSF, or (3) medical therapy plus VPS. The primary outcome is visual field mean deviation change at first of Month 6 (26 weeks) or time of treatment failure of the eligible eye(s), followed by a continuation study to assess time to treatment failure. The determination of eligible eye(s) is based on meeting the eligibility criteria at baseline.

Official Title

Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss

Eligibility Criteria

Ages Eligible for Study: 18 Years to 63 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Heather E. Moss, MD, PhD
Heather E. Moss, MD, PhD
Neuro-ophthalmology specialist
Associate Professor of Ophthalmology and of Neurology
Robert Dodd, MD, PhD
Robert Dodd, MD, PhD
Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Neurosurgeon, Neurosurgeon
Associate Professor of Neurosurgery, of Radiology and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Shannon Beres, MD
Shannon Beres, MD
Neuro-ophthalmology specialist, General neurologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Ophthalmology
Gordon Li, MD
Gordon Li, MD
Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)
Andrea Lora Kossler, MD, FACS
Andrea Lora Kossler, MD, FACS
Assistant Professor of Ophthalmology

Contact us to find out if this trial is right for you.


Mariana Nunez
(650) 497-7846